{"schema":"sb.node.v1","id":"sb:e/b3a6d75cb7b2e6a882fece68","kind":"entity","label":{"text":"cdmo","locale":"en"},"identity":{"anchor":"label:en:cdmo","strength":"label"},"asOf":{"knowledgeCutoff":"2026-10-08T14:59:24.389104+00:00","snapshot":"deploy 4871da00b92fa820ead66cc7cb69b2c6e96a6db9"},"lens":{"kind":"public"},"build":{"plane":"projected","builtFrom":["entity_graph.slim.json","entity_receipts (deploy asset)","event_graph.json","truth_records (deploy asset)","corroborated_record.json"],"rule":"node-projection.entity@v1"},"standing":{"evidence":{"supporting":52,"separatePublishers":22,"basis":"documents that mention the subject and the outlets that carried them; a mention is evidence the referent is in use, not evidence about any claim"},"admission":{"state":"canonical","reason":"entity graph provenance 'curated'; the node carries no promotion receipt in v1","policy":"EQ-PROMOTION (receipt not carried)"},"disposition":{"state":"served","reason":"public record"},"validity":{"from":"2026-05-11","to":"2026-10-07","basis":"first and last day we saw it mentioned; not the subject's own lifetime"},"measurement":{"state":"partial","blind":["assertion coverage 0.308: about 69% of mentions carry no typed assertion"]}},"dimensions":{"domains":["auto","india_south_asia"],"activeDays":26,"assertions":{"regulatory-approval":4,"launch-release":4,"acquisition":3,"utterance":2,"meeting-visit":2,"military-action":1}},"up":[],"upNote":"An entity is a root: it is contained by nothing. Pan out by following R.","children":{"count":11,"byKind":{"observation":11},"withheld":{"state":"withheld","count":1,"reason":"1 receipt withheld: no source link (the same rule the topic record applies)"},"items":[{"id":"sb:o/dc472613ccc73b3baca28667","kind":"observation","label":"Fierce Biotech · 2026-10-05 · How to Choose a Biologics CDMO: 4 Criteria That Matter the Most","url":"https://www.fiercebiotech.com/sponsored/how-choose-biologics-cdmo-4-criteria-matter-most"},{"id":"sb:o/5e247f73b381c283c042ef85","kind":"observation","label":"PE Hub · 2026-09-29 · Riverside backs French medtech CDMO Medical Group in Selenium Medical tie-up","url":"https://www.pehub.com/riverside-backs-french-medtech-cdmo-medical-group-in-selenium-medical-tie-up/"},{"id":"sb:o/5726864ec05e33ece530c4f5","kind":"observation","label":"PE Hub · 2026-09-17 · NewSpring Capital leads financing for cell therapy CDMO merger Kincellis","url":"https://www.pehub.com/newspring-capital-leads-financing-for-cell-therapy-cdmo-merger-kincellis/"},{"id":"sb:o/2974f07a67349aa2ea2b0a32","kind":"observation","label":"Economic Times · 2026-09-14 · ETMarkets AIF Talk | Aerospace, electronics, CDMO, auto ancillaries: Where Rajesh Kothari sees India’s next growth opportunities","url":"https://economictimes.indiatimes.com/markets/expert-view/etmarkets-aif-talk-aerospace-electronics-cdmo-auto-ancillaries-where-rajesh-kothari-sees-indias-next-growth-opportunities/articleshow/134231477.cms"},{"id":"sb:o/5a3649585547721316e476e6","kind":"observation","label":"GEN · 2026-09-11 · 10 CDMO Up & Comers 2026","url":"https://www.genengnews.com/topics/bioprocessing/10-cdmo-up-comers-2026/"},{"id":"sb:o/932dab125f086d6e09dfeddf","kind":"observation","label":"PR Newswire · 2026-09-03 · FIRST IN THE BALTICS: NORTHWAY BIOTECH OPENS €61 MILLION CELL THERAPY AND PERSONALIZED MEDICINE CDMO IN VILNIUS","url":"https://www.prnewswire.com/news-releases/first-in-the-baltics-northway-biotech-opens-61-million-cell-therapy-and-personalized-medicine-cdmo-in-vilnius-302868969.html"},{"id":"sb:o/cdfe8feb0d351a98692e3830","kind":"observation","label":"FDA Drug News · 2026-05-11 · [APPROVAL] Quality CDMO, Inc. - 665961 - 09/11/2024","url":"http://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/quality-cdmo-inc-665961-09112024"},{"id":"sb:o/e8e2fad090694acd2c12ab34","kind":"observation","label":"FDA Drug News · 2026-05-11 · [APPROVAL] Quality CDMO, Inc. - 665961 - 05/01/2026","url":"http://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/quality-cdmo-inc-665961-05012026"},{"id":"sb:o/006503c57a52543559775988","kind":"observation","label":"Seoul Economic Daily · 2026-10-07 · Samsung Biologics' Labor Dispute Erodes Shareholder Value","url":"https://en.sedaily.com/finance/2026/10/07/samsung-biologics-labor-dispute-erodes-shareholder-value"},{"id":"sb:o/7d3f8f4b4c53df1f3a367f5e","kind":"observation","label":"PR Newswire · 2026-10-07 · Resonant Clinical Solutions y Haier Biomedical presentan una innovadora centrífuga de sobremesa","url":"https://www.prnewswire.com/news-releases/resonant-clinical-solutions-y-haier-biomedical-presentan-una-innovadora-centrifuga-de-sobremesa-302901061.html"}],"cursor":"c1.eyJpZCI6InNiOmUvYjNhNmQ3NWNiN2IyZTZhODgyZmVjZTY4IiwibCI6ImNoaWxkcmVuIiwibyI6MTAsImsiOm51bGwsImEiOiIyMDI2LTEwLTA4VDE0OjU5OjI0LjM4OTEwNCswMDowMCJ9","order":"newest first; we keep the 11 newest receipts for this entity. Its other observations are counted in standing.evidence.supporting but are not addressable in v1"},"relations":{"count":10,"byKind":{"co-mentioned":10},"items":[{"kind":"relation","label":"co-mentioned with fda (18 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/c0a9e54b11f07343310d248d"},{"kind":"relation","label":"co-mentioned with europe (15 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/fcb51854aef387dfdc642f27"},{"kind":"relation","label":"co-mentioned with cdmos (11 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/608fc30d53bb538ed6690c30"},{"kind":"relation","label":"co-mentioned with supply chain (11 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/299449a46c080b13fe88d6b4"},{"kind":"relation","label":"co-mentioned with india (10 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/c896ecb8ed6f3846be99b628"},{"kind":"relation","label":"co-mentioned with prnewswire (10 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/03fbf2aee252ef96cac0c95b"},{"kind":"relation","label":"co-mentioned with swiss (10 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/8f4c74ea105e34e8a6d4b043"},{"kind":"relation","label":"co-mentioned with ai (9 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/f1fea367ccef1527cf5dce40"},{"kind":"relation","label":"co-mentioned with size (9 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/e7f941a1d85988abe822f1d4"},{"kind":"relation","label":"co-mentioned with china (8 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/790bf3a24f67fe15d723199a"}],"cursor":null,"order":"situations first, then claims (the subject's own maintained record, then site-wide corroborated clusters; each label ends with its standing), then co-mentions by shared documents, descending. Co-mentions are the ten strongest the entity graph keeps per entity"},"edge":{"state":"continues"},"links":{"rest":"/api/v1/node/e/b3a6d75cb7b2e6a882fece68","mcp":"traverse {\"id\":\"sb:e/b3a6d75cb7b2e6a882fece68\"}","page":"/entity/cdmo/"},"limits":{"levelsPerCall":1,"pageSize":10,"maxPageSize":50,"membersMax":50,"statement":"One level per call: depth is 1 and only 1, and there is no whole-graph dump. pageSize 1-50 (default 10); a page limit is a cursor, never an edge. Members are listed up to 50. At most 60 traverse calls a minute per caller (runaway-loop protection, not a meter). One knowledge cutoff is served: the deploy's."},"actions":[{"verb":"unfold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/b3a6d75cb7b2e6a882fece68\",\"level\":\"children\"}"},{"verb":"fold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/b3a6d75cb7b2e6a882fece68\"}"},{"verb":"panOut","lit":false,"effect":"read","layer":"cantina","reason":"An entity is a root: it is contained by nothing. Pan out by following R."},{"verb":"follow","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/b3a6d75cb7b2e6a882fece68\",\"level\":\"relations\"}"},{"verb":"receipts","lit":false,"effect":"read","layer":"cantina","reason":"receipts are the observations below this node; unfold to reach them"},{"verb":"edge","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/b3a6d75cb7b2e6a882fece68\"}"},{"verb":"asOf","lit":false,"effect":"read","layer":"cantina","reason":"v1 serves one knowledge cutoff, this deploy's; walking an earlier cutoff needs retained history (EQ-REPLAY), which v1 does not keep"},{"verb":"switchObserver","lit":false,"effect":"read","layer":"cantina","reason":"the public record is the same for every observer; traversal through a Watch's lens is not served in v1"},{"verb":"readOriginal","lit":false,"effect":"read","layer":"cantina","reason":"no translation is applied on this node; every label is the source's own text"},{"verb":"save","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"saving applies to a configured Watch; configure one around this node first (free), then save it"},{"verb":"deliver","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"delivery applies to a saved Watch"},{"verb":"format","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"output format applies to a saved Watch"},{"verb":"deltaR","lit":false,"effect":"read","layer":"workshop","reason":"Delta R needs a saved Watch with a previous reading"},{"verb":"read","lit":false,"effect":"read","layer":"docking-bay","reason":"one-time Reads are parked until the Commander decides their shape (#938)"}]}